With great interest, we read the recent article by Tréluyer and colleagues.1 The authors investigated the long-term neurodevelopmental impact of doxapram for preventing apnea of prematurity in a population-based cohort study, using 2:1 propensity score matching. They found no association between the use of doxapram and neurodevelopmental outcomes at age 5–6 years in children born before 32 weeks of gestation. Although the results provide insights into the use and impact of doxapram in premature infants, the authors’ statement that this study might reassure clinicians about the long-term consequences of doxapram in the treatment of apnea of prematurity is, in our opinion, debatable. First, the lack of information about doxapram …

中文翻译：

---

多沙普仑治疗早产儿呼吸暂停——保持平衡的重要性

我们饶有兴趣地阅读了 Tréluyer 及其同事最近发表的文章。1 作者使用 2:1 倾向评分匹配，在一项基于人群的队列研究中调查了多沙普仑预防早产儿呼吸暂停对神经发育的长期影响。他们发现，对于妊娠 32 周之前出生的儿童，使用多沙普仑与 5-6 岁时的神经发育结果之间没有关联。尽管这些结果提供了关于多沙普仑在早产儿中的使用和影响的见解，但我们认为，作者关于这项研究可能使临床医生放心多沙普仑治疗早产儿呼吸暂停的长期后果的说法是值得商榷的。首先，缺乏有关多沙普仑的信息……